pattern cursor banner


This is a unique Gram negative targeted product based on a novel mechanism of action driven by one of its constituent zidebactam (INN for WCK 5107), a β-lactam enhancer combined with a cephalosporin. β-lactam enhancer zidebactam is endowed with dual mechanism of high affinity binding to Gram negative PBP2 ( Penicillin Binding Protein 2 which keeps Gram negative bacteria in a rod shape) and inhibition of β-lactamases which enhance the activity of cephalosporin against diverse MDR Gram negative organisms lending WCK 5222 a clear potential for the broadest ever coverage of life threatening infections.

WCK 5222 : Resistant Pathogen coverage:

  • ESBL Gram negatives including Piperacillin–Tazobactam resistant strains
  • Cefepime resistant Enterobacter with CMY β-lactamase
  • KPC & other CREs with OXA 48/181 β-lactamases
  • MBL/NDM Enterobacteriaceae & Pseudomonas
  • Ceftazidime and Meropenem resistant Pseudomonas
  • Imipenem resistant Acinetobacter
  • Staphylococci, Pneumococci & Streptococci – Paediatric skin to sepsis 3 major Gram positives

WCK 5222 : Indication Potential

  • Hospital acquired Pneumonia and Ventilator associated bacterial pneumonia (VABP)
  • Blood stream infections/ sepsis and complicated
  • Intra-abdominal and urinary tract infections
  • Complicated Urinary tract Infection (CUTI)


    Publications will be here soon

view all